The Academic Department of Biochemistry, the Royal Marsden NHS Foundation Trust, Fulham Rd, London, SW3 6JJ, United Kingdom.
J Clin Oncol. 2010 Sep 10;28(26):4038-44. doi: 10.1200/JCO.2009.27.4290. Epub 2010 Jul 19.
To review the influence of sex hormones on the progression of breast, prostate, gynecologic, and colorectal cancer. The literature was reviewed in an informal manner utilizing the authors' prior knowledge to collate the current evidence for the involvement of sex hormones, particularly estrogens and androgens in the progression of a range of hormonally responsive cancers. In particular, the effect of treatment involving hormone withdrawal treatment was considered strong evidence for involvement. The impact of basal levels of endogenous steroids was considered. Data from clinical trials indicate the efficacy of therapeutic interventions that result in ablation or antagonism of host steroids for a range of cancers. Demonstration of the correlation of the completeness of withdrawal with clinical outcome together with direct evidence of progression from studies looking at the influence of tissue and circulating levels of sex hormones more recently in conjunction with gene expression profiles all provide compelling evidence for the involvement of steroids in the progression of disease. The involvement of steroids in the progression of cancer in hormone-sensitive tissues is well established and an important target for therapy.
探讨性激素对乳腺癌、前列腺癌、妇科癌症和结直肠癌进展的影响。本研究以作者的既有知识为基础，以非正规的方式对文献进行了回顾，以整理性激素（特别是雌激素和雄激素）在一系列激素反应性癌症进展中作用的现有证据。特别是，激素撤退治疗的效果被认为是性激素参与作用的有力证据。本研究还考虑了内源性类固醇的基础水平的影响。临床试验数据表明，针对一系列癌症的宿主类固醇消融或拮抗的治疗干预措施具有疗效。从最近的研究中观察到的组织和循环性激素水平对疾病进展的影响以及与基因表达谱相关的研究，都提供了令人信服的证据，证明类固醇在疾病进展中发挥作用。性激素在激素敏感组织中的癌症进展中发挥作用已得到充分证实，是治疗的重要靶点。
